Thermo Fisher Raises 2025 Guidance After Q3 Beat

Thermo Fisher raised its 2025 revenue guidance to $44.1–$44.5 billion and lifted its annual profit outlook after reporting third-quarter results that beat expectations. The company posted adjusted Q3 EPS of $5.79 and revenue of $11.12 billion, up about 4.9–5% (roughly 3% organic), driven by strength in life‑sciences and lab tools. Management credited strategic deals — including acquisitions of Sanofi’s Ridgefield sterile fill‑finish site and Solventum’s filtration and purification business — operational execution, a $1 billion share buyback and a new AI collaboration for the performance. Thermo Fisher warned revenue from China will be down mid‑to‑high single digits because of China’s bulk medical‑device purchasing program and said near‑term headwinds include U.S. government spending delays and cuts to academic research. Adjusted operating margin improved to roughly 22.6–23.3% while GAAP EPS remained near $4.27, and the stock rose modestly on the results.